Minor adverse events · patients with cutaneous disease in systemic lupus erythematosus
Oral dehydroepiandrosterone probably leads to higher adverse events: minor compared with placebo (moderate certainty).
1 finding from 1 review
Minor adverse events · patients with cutaneous disease in systemic lupus erythematosus
1 finding from 1 review
Minor adverse events · patients with cutaneous disease in systemic lupus erythematosus
Oral methotrexate showed no clear difference in adverse events: minor compared with placebo (moderate certainty).
1 finding from 1 review
Adverse events: other · adults with chronic pain
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Severe adverse events · people with acute ischemic stroke
Citicoline showed no clear difference in severe adverse events compared with placebo or standard treatment (low certainty).
1 finding from 1 review
Severe adverse events · people previously treated with radiosurgery or fractionated radiotherapy to the brain or head and neck region with a diagnosis of brain…
1 finding from 1 review
Adverse events: nausea · people with delirium
Cholinesterase inhibitors (rivastigmine) showed no clear difference in adverse events nausea compared with placebo (low certainty).
1 finding from 1 review
Adverse events: renal · men with advanced prostate cancer
Bisphosphonates probably leads to higher adverse events: renal compared with placebo/no treatment (moderate certainty).
1 finding from 1 review
Sexual adverse events
Silodosin probably leads to higher sexual adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Severe adverse events · people with Friedreich ataxia
Antioxidant showed no clear difference in severe adverse events compared with placebo (low certainty).
1 finding from 1 review
Severe adverse events · newly diagnosed patients with myelodysplastic syndromes
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Non‐serious adverse events Maximum · chronic hepatitis B
It is very uncertain whether radix Sophorae flavescentis changes proportion of participants with 1 or more adverse events considered… compared with no intervention or placebo (very low certainty).
1 finding from 1 review
Serious adverse events · people with CIDP
Intravenous immunoglobulin showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events · postmenopausal women with a higher risk for fracturesa
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Serious adverse events · postmenopausal women at lower risk of fractures1
Intermittent/cyclic etidronate 400 mg/day showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
RR 0.9 [0.52, 1.54]
Studies not reported
Moderate
Serious adverse events · people who smoke
Bupropion showed no clear difference in serious adverse events compared with placebo/no pharmacological treatment (moderate certainty).
1 finding from 1 review
Serious adverse events · children with respiratory syncytial virus infection
Summary of findings table ‐ Immunoglobulins showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events · people with sickle cell disease
Hydroxyurea showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events · people with sickle cell disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · premenopausal women (age 18–32.7 years)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found